Grant: Fellowship - Priority Announcement: Gastroenterology
Université de Sherbrooke
$38,062.00
Colorectal Cancer Cell Growth Inhibition by a Novel Class of Compounds that Alter the Activity of Splicing Regulators
EF 2015-16
Résumé
Alternative splicing (AS) is critical to the expression of more than 90% of human genes. AS produces multiple protein variants from a single gene and thus greatly contributes to the functional complexity and diversity of the proteome. AS profiles are often altered in human disease. Several studies have shown that protein variants with antagonistic activities affecting cell growth are aberrantly produced in cancer cells, including colorectal cancer (CRC). Therefore, controlling aberrant AS events in CRC cells has the potential to provide new ways to prevent or limit the growth of cancer cells. The use of small molecules that alter AS has recently emerged as a promising therapeutic approach for a variety of diseases. However, the number of molecules displaying these properties is limited, and their mechanisms of action, as well as their use in anti-cancer strategies remain largely unexplored.
We have recently identified a novel class of AS-modulating compounds that inhibit the growth of CRC cells in culture. In this project, I will screen and study the effects of these compounds on splicing profiles and on the activity of AS regulators to determine their underlying molecular mechanisms of action. I will also study the impact of the most potent compounds on a variety of parameters associated with CRC progression. As cancer cells may be hyper-sensitive to a decrease in the activity of AS regulators, we expect that our most potent compounds will alter the activity of splicing regulators to modulate AS events that contribute to CRC progression, leading to inhibition of cancer cells growth. This project will elucidate the molecular mechanisms underlying the modulation of AS by a new class of compounds and assess their impact on CRC progression. Overall, my project will identify new molecules with anti-cancer properties, thereby establishing the therapeutic value of AS modulating agents in CRC.
Programme
Fellowship - Priority Announcement: Gastroenterology
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
339965
Name
Sohail Muhammad
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Colorectal Cancer Cell Growth Inhibition by a Novel Class of Compounds that Alter the Activity of Splicing Regulators
Programtype2
Fellowship Programs
Orgnameinp2
Université de Sherbrooke
Cihramount2
$38,062
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Gastroenterology
Keyworddelim
Alternative Splicing; Cell Proliferation; Colorectal Cancer; Drug Discovery; Rna Binding Proteins; Tumor Growth
Abstract
Alternative splicing (AS) is critical to the expression of more than 90% of human genes. AS produces multiple protein variants from a single gene and thus greatly contributes to the functional complexity and diversity of the proteome. AS profiles are often altered in human disease. Several studies have shown that protein variants with antagonistic activities affecting cell growth are aberrantly produced in cancer cells, including colorectal cancer (CRC). Therefore, controlling aberrant AS events in CRC cells has the potential to provide new ways to prevent or limit the growth of cancer cells. The use of small molecules that alter AS has recently emerged as a promising therapeutic approach for a variety of diseases. However, the number of molecules displaying these properties is limited, and their mechanisms of action, as well as their use in anti-cancer strategies remain largely unexplored.
We have recently identified a novel class of AS-modulating compounds that inhibit the growth of CRC cells in culture. In this project, I will screen and study the effects of these compounds on splicing profiles and on the activity of AS regulators to determine their underlying molecular mechanisms of action. I will also study the impact of the most potent compounds on a variety of parameters associated with CRC progression. As cancer cells may be hyper-sensitive to a decrease in the activity of AS regulators, we expect that our most potent compounds will alter the activity of splicing regulators to modulate AS events that contribute to CRC progression, leading to inhibition of cancer cells growth. This project will elucidate the molecular mechanisms underlying the modulation of AS by a new class of compounds and assess their impact on CRC progression. Overall, my project will identify new molecules with anti-cancer properties, thereby establishing the therapeutic value of AS modulating agents in CRC.
Competitiondate
201511
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Sohail, Muhammad
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $38,062~ $0~